{"meta":{"totalResults":3,"from":0},"results":[{"aliases":[{"type":"USBrandName","name":"Opdivo"},{"type":"CodeName","name":"CMAB819"},{"type":"Synonym","name":"nivolumab biosimilar CMAB819"},{"type":"Abbreviation","name":"NIVO"},{"type":"CodeName","name":"MDX-1106"},{"type":"CodeName","name":"ONO-4538"},{"type":"CodeName","name":"BMS-936558"},{"type":"Synonym","name":"nivolumab biosimilar ABP 206"},{"type":"Synonym","name":"nivolumab biosimilar BCD-263"},{"type":"CodeName","name":"ABP 206"},{"type":"CASRegistryName","name":"946414-94-4"}],"definition":{"html":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","text":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab","text":"Nivolumab"},"nciConceptId":"C68814","nciConceptName":"Nivolumab","termId":539733,"name":"nivolumab","firstLetter":"n","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"nivolumab"},{"aliases":[{"type":"USBrandName","name":"Opdivo Qvantig"},{"type":"Synonym","name":"nivolumab and recombinant human hyaluronidase"},{"type":"Synonym","name":"nivolumab and rHuPH20"},{"type":"Synonym","name":"nivolumab/recombinant human hyaluronidase"},{"type":"Synonym","name":"hyaluronidase-nvhy and nivolumab"},{"type":"Synonym","name":"hyaluronidase/nivolumab"}],"definition":{"html":"A co-formulation composed of nivolumab, a fully human immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), and a recombinant form of human hyaluronidase, with potential immune checkpoint inhibitory and antineoplastic activities. Upon subcutaneous administration of nivolumab and hyaluronidase-nvhy, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity. Hyaluronidase hydrolyzes and degrades the glycosaminoglycan hyaluronic acid (HA), thereby decreasing interstitial viscosity and enhancing penetration of nivolumab through the interstitial space. This facilitates the delivery of nivolumab.","text":"A co-formulation composed of nivolumab, a fully human immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), and a recombinant form of human hyaluronidase, with potential immune checkpoint inhibitory and antineoplastic activities. Upon subcutaneous administration of nivolumab and hyaluronidase-nvhy, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity. Hyaluronidase hydrolyzes and degrades the glycosaminoglycan hyaluronic acid (HA), thereby decreasing interstitial viscosity and enhancing penetration of nivolumab through the interstitial space. This facilitates the delivery of nivolumab."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab-and-hyaluronidase-nvhy","text":"Nivolumab and Hyaluronidase-nvhy"},"nciConceptId":"C212985","nciConceptName":"Nivolumab and Recombinant Human Hyaluronidase","termId":817311,"name":"nivolumab and hyaluronidase-nvhy","firstLetter":"n","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"nivolumab-and-recombinant-human-hyaluronidase"},{"aliases":[{"type":"USBrandName","name":"Opdualag"},{"type":"Synonym","name":"nivolumab-relatlimab-rmbw"},{"type":"Synonym","name":"nivolumab/relatlimab-rmbw injectable formulation"},{"type":"Synonym","name":"relatlimab-rmbw/nivolumab"},{"type":"Synonym","name":"relatlimab-rmbw-nivolumab"},{"type":"Synonym","name":"relatlimab-rmbw and nivolumab"},{"type":"Synonym","name":"Opdivo/relatlimab-rmbw"},{"type":"CodeName","name":"BMS 986213"},{"type":"CodeName","name":"BMS-986213"},{"type":"CodeName","name":"BMS986213"},{"type":"Synonym","name":"nivolumab and relatlimab-rmbw"},{"type":"Synonym","name":"nivolumab and relatlimab"}],"definition":{"html":"An injectable fixed-dose combination formulation composed of nivolumab, a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), and relatlimab-rmbw, a human IgG4 monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration of nivolumab and relatlimab-rmbw, nivolumab binds to and blocks the activation of PD-1 by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This prevents PD-1-mediated signaling and PD-1-mediated inhibition of the immune response. Relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs) and prevents LAG-3 binding to major histocompatibility complex (MHC) class II. This prevents LAG-3-mediated signaling and LAG-3-mediated inhibition of the immune response. Together, blocking these two immune checkpoints re-activates the immune system, increases cytotoxic T lymphocytes (CTLs) proliferation and activation, and leads to a reduction in tumor growth. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity. LAG-3 expression on TILs is associated with tumor-mediated immune suppression.","text":"An injectable fixed-dose combination formulation composed of nivolumab, a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), and relatlimab-rmbw, a human IgG4 monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration of nivolumab and relatlimab-rmbw, nivolumab binds to and blocks the activation of PD-1 by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This prevents PD-1-mediated signaling and PD-1-mediated inhibition of the immune response. Relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs) and prevents LAG-3 binding to major histocompatibility complex (MHC) class II. This prevents LAG-3-mediated signaling and LAG-3-mediated inhibition of the immune response. Together, blocking these two immune checkpoints re-activates the immune system, increases cytotoxic T lymphocytes (CTLs) proliferation and activation, and leads to a reduction in tumor growth. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity. LAG-3 expression on TILs is associated with tumor-mediated immune suppression."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab-and-relatlimab-rmbw","text":"Nivolumab and Relatlimab-rmbw"},"nciConceptId":"C186440","nciConceptName":"Nivolumab/Relatlimab-rmbw","termId":809169,"name":"nivolumab/relatlimab-rmbw","firstLetter":"n","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"nivolumab-relatlimab-rmbw"}],"links":null}